(2023). Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP-4 inhibitors: population-based cohort study. Clin Pharmacol Ther. http://doi.org/10.1002/cpt.2975.
(2022). Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1584.
(2021). Utilization and long-term persistence of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15046.